New P.E. Drug Approved In Europe While Premature Ejaculation Cure Remains Out of Reach to Am...( Demand for o...),Health

Demand for one of the leading, anti-premature ejaculation formulas is expected to soar after regulatory approvals for the first medicine for premature ejaculation are granted outside of the United States.

Los Angeles, CA (PRWEB) April 3, 2009 -- American men who eagerly await an FDA approved premature ejaculation pill will find no relief from the overseas approval of dapoxetine. Marketed under the brand name Priligy™, dapoxetine has been approved for medical use in Sweden and Finland, but was rejected for use at this time by the U.S. Federal Drug Administration.

"The need remains to develop libido products that are suitable alternatives to drugs and not only help men last longer and offer the chance at healthy, satisfying sex lives, but are safe and detached of potentially harmful side effects," stated W. Baclini, founder of one of the most respected manufacturers of male health and performance supplements, Zurich Medical Labs in Los Angeles, California.

An estimated 30 million adult men in the United States endure problems with premature ejaculation, a condition thought to affect up to 30% of the male population worldwide. Health experts attribute lack of climax control to low levels of naturally produced brain chemical, serotonin. This important 'feel-good' neurotransmitter is responsible for regulating mood and mental faculties, promoting proper nervous system function and helps prolong orgasm.

Dapoxetine is among a class of selective serotonin reuptake inhibitor (SSRI) drugs that include antidepressants which are widely used to stimulate production of serotonin to last longer in bed. Major drug intolerances
'/>"/>